英語醫(yī)學(xué)論文寫作實例分析

1、最大限度地展示您的研究成果最大限度地展示您的研究成果 英語醫(yī)學(xué)論文寫作實例分析英語醫(yī)學(xué)論文寫作實例分析 論文核心內(nèi)容論文核心內(nèi)容 1）標(biāo)題）標(biāo)題 2）摘要）摘要 3）正文）正文 論文核心內(nèi)容論文核心內(nèi)容 1）標(biāo)題）標(biāo)題 目的：在第一時刻抓住讀者審稿人的目光目的：在第一時刻抓住讀者審稿人的目光 論文核心內(nèi)容論文核心內(nèi)容 1）標(biāo)題）標(biāo)題 目的：在第一時刻抓住讀者審稿人的目光目的：在第一時刻抓住讀者審稿人的目光 技巧：把主要研究結(jié)果技巧：把主要研究結(jié)果 “裝入裝入” 標(biāo)題標(biāo)題 論文核心內(nèi)容論文核心內(nèi)容 1）標(biāo)題）標(biāo)題 2）摘要）摘要 目的：吸引讀者審稿人引入正文目的：吸引讀者審稿人引入正文 論文核心

2、內(nèi)容論文核心內(nèi)容 1）標(biāo)題）標(biāo)題 2）摘要）摘要 目的：吸引讀者審稿人引入正文目的：吸引讀者審稿人引入正文 技巧：給出一個基本獨立的技巧：給出一個基本獨立的“故事梗概故事梗概” 論文核心內(nèi)容論文核心內(nèi)容 1）標(biāo)題）標(biāo)題 2）摘要）摘要 3）正文）正文 目的：將一個完整的目的：將一個完整的 “故事故事” 呈現(xiàn)給讀者呈現(xiàn)給讀者 論文核心內(nèi)容論文核心內(nèi)容 1）標(biāo)題）標(biāo)題 2）摘要）摘要 3）正文）正文 目的：將一個完整的目的：將一個完整的 “故事故事” 呈現(xiàn)給讀者呈現(xiàn)給讀者 技巧：換位思維，撰寫稿件時以讀者為中心技巧：換位思維，撰寫稿件時以讀者為中心 Effects of nifedipine on

3、 blood pressure in patients with primary hypertension vs. healthy controls Effects of nifedipine on blood pressure in patients with primary hypertension vs. healthy controls Nifedipine decreases blood pressure in patients with primary hypertension but not in healthy controls Abstract The present stu

4、dy examined the role of dopamine D4 receptor on prepulse inhibition in rats. Gating deficit was induced pharmacologically using ketamine. Rats then received daily treatment with the D4-selective antagonist CP-293,019 vs. saline. . Abstract Abberant information processing (e.g., gating deficit) is th

5、e basis of many cognitive deficits in schizophrenia. Since dopamine D4 receptor is elevated in the brain of schizophrenia patients, we examined whether D4 receptor antagonism could alleviate gating deficit in a rat model. Prepulse inhibition was disrupted . International Journal of Radiation Oncolog

6、y Biology Physics, 67:888-896, 2007 Due to the complex molecular pathogenesis of glioblastoma multiforme, therapeutic strategies are evolving from cytotoxic therapies to molecular approaches which target specific signaling cascades that promote tumor growth such as cyclooxygenase- 2 (COX-2), a rate-

7、limiting enzyme in conversion of arachidonic acid into prostaglandins. International Journal of Radiation Oncology Biology Physics, 67:888-896, 2007 Due to the complex molecular pathogenesis of glioblastoma multiforme, therapeutic strategies are evolving from cytotoxic therapies to molecular approac

8、hes which target specific signaling cascades that promote tumor growth such as cyclooxygenase- 2 (COX-2), a rate-limiting enzyme in conversion of arachidonic acid into prostaglandins. International Journal of Radiation Oncology Biology Physics, 67:888-896, 2007 Due to the complex molecular pathogene

9、sis of glioblastoma multiforme, therapeutic strategies are evolving from cytotoxic therapies to molecular approaches which target specific signaling cascades that promote tumor growth such as cyclooxygenase- 2 (COX-2), a rate-limiting enzyme in conversion of arachidonic acid into prostaglandins. Int

10、ernational Journal of Radiation Oncology Biology Physics, 67:888-896, 2007 Due to the complex molecular pathogenesis of glioblastoma multiforme, therapeutic strategies are evolving from cytotoxic therapies to molecular approaches which target specific signaling cascades that promote tumor growth suc

11、h as cyclooxygenase- 2 (COX-2), a rate-limiting enzyme in conversion of arachidonic acid into prostaglandins. International Journal of Radiation Oncology Biology Physics, 67:888-896, 2007 Due to the complex molecular pathogenesis of glioblastoma multiforme, therapeutic strategies are evolving from c

12、ytotoxic therapies to molecular approaches which target specific signaling cascades that promote tumor growth such as cyclooxygenase- 2 (COX-2), a rate-limiting enzyme in conversion of arachidonic acid into prostaglandins. International Journal of Radiation Oncology Biology Physics, 67:888-896, 2007

13、 Due to the complex molecular pathogenesis of glioblastoma multiforme, therapeutic strategies are evolving from cytotoxic therapies to molecular approaches which target specific signaling cascades that promote tumor growth such as cyclooxygenase- 2 (COX-2), a rate-limiting enzyme in conversion of ar

14、achidonic acid into prostaglandins. Despite of the complex molecular pathogenesis of glioblastoma multiforme, therapeutic strategies are evolving from cytotoxic therapies to molecular approaches. Due to the complex molecular pathogenesis of glioblastoma multiforme, therapeutic strategies are evolvin

15、g from cytotoxic therapies to molecular approaches which target specific signaling cascades that promote tumor growth such as cyclooxygenase-2 (COX-2), a rate-limiting enzyme in conversion of arachidonic acid into prostaglandins. Despite of the complex molecular pathogenesis of glioblastoma multifor

16、me, therapeutic strategies are evolving from cytotoxic therapies to molecular approaches. Activation of cyclooxygenase-2 (COX-2), the rate-limiting enzyme in prostaglandin biosynthesis, promotes tumor growth, and therefore represents a promising target for intervention. Due to the complex molecular

17、pathogenesis of glioblastoma multiforme, therapeutic strategies are evolving from cytotoxic therapies to molecular approaches which target specific signaling cascades that promote tumor growth such as cyclooxygenase-2 (COX-2), a rate-limiting enzyme in conversion of arachidonic acid into prostagland

18、ins. Results In order to examine the effects of sitagliptin on glucose level, diabetic rats were treated with various doses of sitagliptin. The blood glucose level was significantly different between the H and M groups compared with the C group. However, the L group was not statistically different f

19、rom the C group. Results In order to examine the effects of sitagliptin on glucose level, diabetic rats were treated with various doses of sitagliptin. The blood glucose level was significantly different between the H and M groups compared with the C group. However, the L group was not statistically

20、 different from the C group. Results In order to examine the effects of sitagliptin on glucose level, diabetic rats were treated with various doses of sitagliptin. The blood glucose level was significantly different between the H and M groups compared with the C group. However, the L group was not s

21、tatistically different from the C group. Results In order to examine the effects of sitagliptin on glucose level, diabetic rats were treated with various doses of sitagliptin. The blood glucose level was significantly different between the H and M groups compared with the C group. However, the L gro

22、up was not statistically different from the C group. Results In order to examine the effects of sitagliptin on glucose level, diabetic rats were treated with various doses of sitagliptin. The blood glucose level was significantly different between the H and M groups compared with the C group. Howeve

23、r, the L group was not statistically different from the C group. Results In order to examine the effects of sitagliptin on glucose level, diabetic rats were treated with various doses of sitagliptin. The blood glucose level was significantly different between the H and M groups compared with the C g

24、roup. However, the L group was not statistically different from the C group. Results Sitagliptin significantly decreased blood glucose concentration in diabetic rats at 150 and 75 mg/kg/d, but not at a lower dose of 37.5 mg/kg/d. Lung cancer is one of the most frequent human cancers and the leading

25、cause of cancer-related deaths in both men and women in the United States and around the world. Non-small cell lung carcinoma (NSCLC) constitutes approximately 80% of all primary lung cancers with a 5-year relative survival of 15%. Prognostic factors usually were helpful in the clinic management and

26、 response evaluation for therapy in lung cancer, which could identify subsets of patients with worse prognosis who might benefit from a more aggressive treatment strategy. For example, the TNM staging system is clinically used to guide treatment decisions and predict prognosis for patients with NSCL

27、C. Poor differentiation, vascular invasion, and inadequate lymph node dissection have been suggested as factors to be considered for deciding on the need or the extent of adjuvant therapy in stage I-II NSCLC. However, the fact that disease relapse rates are as high as 30%, even among stage IA patien

28、ts, has led to an interest in identifying additional prognostic factors for NSCLC. Lung cancer is one of the most frequent human cancers and the leading cause of cancer-related deaths in both men and women in the United States and around the world. Non-small cell lung carcinoma (NSCLC) constitutes a

29、pproximately 80% of all primary lung cancers with a 5-year relative survival of 15%. Prognostic factors usually were helpful in the clinic management and response evaluation for therapy in lung cancer, which could identify subsets of patients with worse prognosis who might benefit from a more aggres

30、sive treatment strategy. For example, the TNM staging system is clinically used to guide treatment decisions and predict prognosis for patients with NSCLC. Poor differentiation, vascular invasion, and inadequate lymph node dissection have been suggested as factors to be considered for deciding on th

31、e need or the extent of adjuvant therapy in stage I-II NSCLC. However, the fact that disease relapse rates are as high as 30%, even among stage IA patients, has led to an interest in identifying additional prognostic factors for NSCLC. 內(nèi)容：細(xì)胞吸附因子內(nèi)容：細(xì)胞吸附因子 預(yù)后預(yù)后 目標(biāo)雜志：目標(biāo)雜志：Lung Cancer Lung cancer is one

32、 of the most frequent human cancers and the leading cause of cancer-related deaths in both men and women in the United States and around the world. Lung cancer is one of the most frequent human cancers and the leading cause of cancer-related deaths in both men and women in the United States and arou

33、nd the world. Lung cancer is one of the most frequent human cancers and the leading cause of cancer-related deaths in both men and women in the United States and around the world. Non-small cell lung carcinoma (NSCLC) constitutes approximately 80% of all primary lung cancers with a 5-year relative s

34、urvival of 15%. Non-small cell lung carcinoma (NSCLC) constitutes approximately 80% of all primary lung cancers with a 5-year relative survival of 15%. Prognostic factors usually were helpful in the clinic management and response evaluation for therapy in lung cancer, which could identify subsets of

35、 patients with worse prognosis who might benefit from a more aggressive treatment strategy. Prognostic factors usually were helpful in the clinic management and response evaluation for therapy in lung cancer, which could identify subsets of patients with worse prognosis who might benefit from a more

36、 aggressive treatment strategy. Prognostic factors usually were helpful in the clinic management and response evaluation for therapy in lung cancer, which could identify subsets of patients with worse prognosis who might benefit from a more aggressive treatment strategy. Prognostic factors usually w

37、ere helpful in the clinic management and response evaluation for therapy in lung cancer, which could identify subsets of patients with worse prognosis who might benefit from a more aggressive treatment strategy. For example, the TNM staging system is clinically used to guide treatment decisions and

38、predict prognosis for patients with NSCLC. For example, the TNM staging system is clinically used to guide treatment decisions and predict prognosis for patients with NSCLC. Prognostic factors usually were helpful in the clinic management and response evaluation for therapy in lung cancer, which cou

39、ld identify subsets of patients with worse prognosis who might benefit from a more aggressive treatment strategy. For example, the TNM staging system is clinically used to guide treatment decisions and predict prognosis for patients with NSCLC. Poor differentiation, vascular invasion, inadequate lym

40、ph node dissection and extracapsular spread have been suggested as factors to be considered for deciding on the need or the extent of adjuvant therapy in stage I-II NSCLC. Poor differentiation, vascular invasion, and inadequate lymph node dissection have been suggested as factors to be considered fo

41、r deciding on the need or the extent of adjuvant therapy in stage I-II NSCLC. However, the fact that disease relapse rates are as high as 30%, even among stage IA patients, has led to an interest in identifying additional prognostic factors for NSCLC. However, the fact that disease relapse rates are

42、 as high as 30%, even among stage IA patients, has led to an interest in identifying additional prognostic factors for NSCLC. However, the fact that disease relapse rates are as high as 30%, even among stage IA patients, has led to an interest in identifying additional prognostic factors for NSCLC. Non-small cell lung carcinoma (NSCLC) constitutes approximately 80% of all primary lung cancers, and has relatively